Search

Author/Creator Fioretto, P.

1. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Issue 7 (3rd July 2017)

Authors:
Avogaro, A.; Giaccari, A.; Fioretto, P.; Genovese, S.; Purrello, F.; Giorgino, F.; Del Prato, S.
Journal:
Expert review of clinical pharmacology
Issue:
Volume 10:Issue 7(2017)
Page Start:
763
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A prediction model to assess the risk of egfr loss in patients with type 2 diabetes and preserved kidney function: The amd annals initiative. (October 2022)

Authors:
Russo, G.T.; Giandalia, A.; Ceriello, A.; Di Bartolo, P.; Di Cianni, G.; Fioretto, P.; Giorda, C.B.; Manicardi, V.; Pontremoli, R.; Viazzi, F.; Lucisano, G.; Nicolucci, A.; De Cosmo, S.
Journal:
Diabetes research and clinical practice
Issue:
Volume 192(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗